PILANCI, K. N. Et Al. 2016. Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study. CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.78, no.1 , 143-150.

PILANCI, K. N., Saglam, S., Okyar, A., YÜCEL, S., Pala-Kara, Z., Ordu, C., ... Namal, E.(2016). Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study. CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.78, no.1, 143-150.

PILANCI, Kezban Et Al. "Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study," CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.78, no.1, 143-150, 2016

PILANCI, Kezban N. Et Al. "Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study." CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.78, no.1, pp.143-150, 2016

PILANCI, K. N. Et Al. (2016) . "Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study." CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.78, no.1, pp.143-150.

@article{article, author={Kezban Nur PİLANCI Et Al. }, title={Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study}, journal={CANCER CHEMOTHERAPY AND PHARMACOLOGY}, year=2016, pages={143-150} }